Lilly's Donanemab, a drug developed for the treatment of Alzheimer's disease, has received a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). This designation is given to drugs that show potential to significantly improve the treatment or prevention of serious diseases.